The stock of Pulmonx Corp (LUNG) has seen a -3.63% decrease in the past week, with a -36.86% drop in the past month, and a -51.46% decrease in the past quarter. The volatility ratio for the week is 9.79%, and the volatility levels for the past 30 days are at 10.55% for LUNG. The simple moving average for the past 20 days is -23.27% for LUNG’s stock, with a -49.96% simple moving average for the past 200 days.
Is It Worth Investing in Pulmonx Corp (NASDAQ: LUNG) Right Now?
Moreover, the 36-month beta value for LUNG is 0.57. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for LUNG is 35.64M and currently, short sellers hold a 3.35% of that float. On May 14, 2025, LUNG’s average trading volume was 413.70K shares.
LUNG) stock’s latest price update
Pulmonx Corp (NASDAQ: LUNG)’s stock price has gone decline by -9.92 in comparison to its previous close of 3.68, however, the company has experienced a -3.63% decrease in its stock price over the last five trading days. globenewswire.com reported 2025-05-01 that REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) — Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Wednesday, May 14, 2025, at 9:35 AM PT / 12:35 PM ET.
Analysts’ Opinion of LUNG
Many brokerage firms have already submitted their reports for LUNG stocks, with D. Boral Capital repeating the rating for LUNG by listing it as a “Buy.” The predicted price for LUNG in the upcoming period, according to D. Boral Capital is $17 based on the research report published on March 10, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see LUNG reach a price target of $7.50, previously predicting the price at $17. The rating they have provided for LUNG stocks is “Neutral” according to the report published on December 11th, 2024.
Lake Street gave a rating of “Buy” to LUNG, setting the target price at $12 in the report published on June 04th of the previous year.
LUNG Trading at -43.96% from the 50-Day Moving Average
After a stumble in the market that brought LUNG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.75% of loss for the given period.
Volatility was left at 10.55%, however, over the last 30 days, the volatility rate increased by 9.79%, as shares sank -38.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -60.01% lower at present.
During the last 5 trading sessions, LUNG fell by -3.63%, which changed the moving average for the period of 200-days by -57.72% in comparison to the 20-day moving average, which settled at $4.32. In addition, Pulmonx Corp saw -51.18% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LUNG starting from French Glendon E. III, who sale 20,000 shares at the price of $7.85 back on Mar 20 ’25. After this action, French Glendon E. III now owns 991,974 shares of Pulmonx Corp, valued at $157,000 using the latest closing price.
GLENDON FRENCH, the Director of Pulmonx Corp, proposed sale 60,000 shares at $7.77 during a trade that took place back on Mar 20 ’25, which means that GLENDON FRENCH is holding shares at $466,200 based on the most recent closing price.
Stock Fundamentals for LUNG
Current profitability levels for the company are sitting at:
- -0.66 for the present operating margin
- 0.74 for the gross margin
The net margin for Pulmonx Corp stands at -0.65. The total capital return value is set at -0.46. Equity return is now at value -60.68, with -36.21 for asset returns.
Based on Pulmonx Corp (LUNG), the company’s capital structure generated 0.42 points at debt to capital in total, while cash flow to debt ratio is standing at -0.58. The debt to equity ratio resting at 0.73. The interest coverage ratio of the stock is -16.95.
Currently, EBITDA for the company is -50.79 million with net debt to EBITDA at 0.29. When we switch over and look at the enterprise to sales, we see a ratio of 1.32. The receivables turnover for the company is 5.99for trailing twelve months and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.97.
Conclusion
To wrap up, the performance of Pulmonx Corp (LUNG) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
